ADCYAP1 and depressive symptom measurement: Altogether, these data suggest that PACAP is involved in migraine and depression (Figure 2), indicating another molecular target that could be assessed to develop new pharmacological tools to enlarge the therapeutic armamentarium available to address both clinical entities.